Related references
Note: Only part of the references are listed.Combination Treatment of Human Pancreatic Cancer Xenograft Models with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib and Oncolytic Herpes Simplex Virus HF10
Kazuo Yamamura et al.
ANNALS OF SURGICAL ONCOLOGY (2014)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer
Brenda K. Edwards et al.
CANCER (2014)
Interleukin-1 beta promotes hypoxia-induced apoptosis of glioblastoma cells by inhibiting hypoxia-inducible factor-1 mediated adrenomedullin production
W. Sun et al.
CELL DEATH & DISEASE (2014)
The reduction of tumor interstitial fluid pressure by liposomal imatinib and its effect on combination therapy with liposomal doxorubicin
Yuchen Fan et al.
BIOMATERIALS (2013)
An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer
Toshiaki Tsuji et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Annual Report to the Nation on the Status of Cancer, 19752009, Featuring the Burden and Trends in Human Papillomavirus (HPV)Associated Cancers and HPV Vaccination Coverage Levels
Ahmedin Jemal et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
VEGF Blockade Enables Oncolytic Cancer Virotherapy in Part by Modulating Intratumoral Myeloid Cells
Mark A. Currier et al.
MOLECULAR THERAPY (2013)
Impact of novel oncolytic virus HF10 on cellular components of the tumor microenviroment in patients with recurrent breast cancer
T. T. Sahin et al.
CANCER GENE THERAPY (2012)
Bevacizumab With Angiostatin-armed oHSV Increases Antiangiogenesis and Decreases Bevacizumab-induced Invasion in U87 Glioma
Wei Zhang et al.
MOLECULAR THERAPY (2012)
Oncolytic Herpes Simplex Virus Counteracts the Hypoxia-Induced Modulation of Glioblastoma Stem-Like Cells
Donatella Sgubin et al.
STEM CELLS TRANSLATIONAL MEDICINE (2012)
A phase I dose-escalation clinical trial of intraoperative direct intratumoral injection of HF10 oncolytic virus in non-resectable patients with advanced pancreatic cancer
A. Nakao et al.
CANCER GENE THERAPY (2011)
Impact of tumor microenvironment on oncolytic viral therapy
Jeffrey Wojton et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2010)
Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice
Timothy Kottke et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
VEGF-A expression by HSV-1-infected cells drives corneal lymphangiogenesis
Todd R. Wuest et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
Enhanced Antitumor Efficacy of Vasculostatin (Vstat120) Expressing Oncolytic HSV-1
Jayson Hardcastle et al.
MOLECULAR THERAPY (2010)
HSV immune complex (HSV-IgG: IC) and HSV-DNA elicit the production of angiogenic factor VEGF and MMP-9
Kozaburo Hayashi et al.
ARCHIVES OF VIROLOGY (2009)
Hypoxia enhances the replication of oncolytic herpes simplex virus in p53- breast cancer cells
Michael Fasullo et al.
CELL CYCLE (2009)
Hypoxia Enhances the Replication of Oncolytic Herpes Simplex Virus
Manish K. Aghi et al.
MOLECULAR THERAPY (2009)
Bevacizumab Increases Viral Distribution in Human Anaplastic Thyroid Carcinoma Xenografts and Enhances the Effects of E1A-Defective Adenovirus d/922-947
Silvana Libertini et al.
CLINICAL CANCER RESEARCH (2008)
Non-engineered, naturally oncolytic herpes simplex virus HSV1 HF-10: Applications for cancer gene therapy
Akihiro Nawa et al.
CURRENT GENE THERAPY (2008)
Oncolytic virotherapy for malignant melanoma with herpes simplex virus type 1 mutant HF10
Daisuke Watanabe et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2008)
Oncolytic HSV-1 infection of tumors induces angiogenesis and upregulates CYR61
Kazuhiko Kurozumi et al.
MOLECULAR THERAPY (2008)
Effect of tumor microenvironment modulation on the efficacy of oncolytic virus therapy
Kazuhiko Kurozumi et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow
Caroline J. Breitbach et al.
MOLECULAR THERAPY (2007)
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Ta-Chiang Liu et al.
NATURE CLINICAL PRACTICE ONCOLOGY (2007)
Angiogenic response caused by oncolytic herpes simplex virus-induced reduced thrombospondin expression can be prevented by specific viral mutations or by administering a thrombospondin-derived peptide
Manish Aghi et al.
CANCER RESEARCH (2007)
Pilot study of oncolytic viral therapy using mutant herpes simplex virus (HF10) against recurrent metastatic breast cancer
Hideto Kimata et al.
ANNALS OF SURGICAL ONCOLOGY (2006)
Flow cytometry: A new approach for the molecular profiling of breast cancer
A Lostumbo et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2006)
Recent progress in the battle between oncolytic viruses and tumours
KA Parato et al.
NATURE REVIEWS CANCER (2005)
Selectivity of an oncolytic herpes simplex virus for cells expressing the DF3/MUC1 antigen
H Kasuya et al.
CANCER RESEARCH (2004)
High interstitial fluid pressure -: An obstacle in cancer therapy
CH Heldin et al.
NATURE REVIEWS CANCER (2004)
Employing tumor hypoxia to enhance oncolytic viral therapy in breast cancer
RH Pin et al.
SURGERY (2004)
Oncolytic viral therapy for breast cancer with herpes simplex virus type 1 mutant HF 10
O Teshigahara et al.
JOURNAL OF SURGICAL ONCOLOGY (2004)
Oncolytic viral therapy using a spontaneously generated herpes simplex virus type 1 variant for disseminated peritoneal tumor in immunocompetent mice
H Takakuwa et al.
ARCHIVES OF VIROLOGY (2003)
Oncolytic herpes simplex virus vectors for cancer virotherapy
S Varghese et al.
CANCER GENE THERAPY (2002)
Control of stromal keratitis by inhibition of neovascularization
M Zheng et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Share Paper
